{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T19:37:41Z","timestamp":1789328261604,"version":"build-2803163510"},"reference-count":117,"publisher":"Springer Science and Business Media LLC","issue":"S2","license":[{"start":{"date-parts":[[2024,6,24]],"date-time":"2024-06-24T00:00:00Z","timestamp":1719187200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,6,24]],"date-time":"2024-06-24T00:00:00Z","timestamp":1719187200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hepatol Int"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1007\/s12072-024-10661-x","type":"journal-article","created":{"date-parts":[[2024,6,24]],"date-time":"2024-06-24T06:02:05Z","timestamp":1719208925000},"page":"909-921","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["MAFLD in adults: non-invasive tests for diagnosis and monitoring of MAFLD"],"prefix":"10.1007","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9105-5837","authenticated-orcid":false,"given":"Wah-Kheong","family":"Chan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent Wai-Sun","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leon A.","family":"Adams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mindie H.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,24]]},"reference":[{"key":"10661_CR1","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","volume":"73","author":"M Eslam","year":"2020","unstructured":"Eslam M, Newsome PN, Sarin SK, Anstee QM, Targher G, Romero-Gomez M, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol. 2020;73:202\u2013209","journal-title":"J Hepatol"},{"key":"10661_CR2","doi-asserted-by":"publisher","first-page":"2691","DOI":"10.1210\/clinem\/dgac321","volume":"107","author":"KE Chan","year":"2022","unstructured":"Chan KE, Koh TJL, Tang ASP, Quek J, Yong JN, Tay P, et al. Global prevalence and clinical characteristics of metabolic-associated fatty liver disease: a meta-analysis and systematic review of 10 739 607 individuals. J Clin Endocrinol Metab. 2022;107:2691\u20132700","journal-title":"J Clin Endocrinol Metab"},{"key":"10661_CR3","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1002\/hep.29085","volume":"65","author":"PS Dulai","year":"2017","unstructured":"Dulai PS, Singh S, Patel J, Soni M, Prokop LJ, Younossi Z, et al. Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta-analysis. Hepatology. 2017;65:1557\u20131565","journal-title":"Hepatology"},{"key":"10661_CR4","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1111\/apt.15673","volume":"51","author":"C Estes","year":"2020","unstructured":"Estes C, Chan HL, Chien RN, Chuang WL, Fung J, Goh GBB, et al. Modelling NAFLD disease burden in four Asian regions\u20142019\u20132030. Aliment Pharmacol Ther. 2020;51:801\u2013811","journal-title":"Aliment Pharmacol Ther"},{"key":"10661_CR5","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/1471-230X-6-33","volume":"6","author":"G Bedogni","year":"2006","unstructured":"Bedogni G, Bellentani S, Miglioli L, Masutti F, Passalacqua M, Castiglione A, et al. The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol. 2006;6:33","journal-title":"BMC Gastroenterol"},{"key":"10661_CR6","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.dld.2009.08.002","volume":"42","author":"JH Lee","year":"2010","unstructured":"Lee JH, Kim D, Kim HJ, Lee CH, Yang JI, Kim W, et al. Hepatic steatosis index: a simple screening tool reflecting nonalcoholic fatty liver disease. Dig Liver Dis. 2010;42:503\u2013508","journal-title":"Dig Liver Dis"},{"key":"10661_CR7","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1053\/j.gastro.2009.06.005","volume":"137","author":"A Kotronen","year":"2009","unstructured":"Kotronen A, Peltonen M, Hakkarainen A, Sevastianova K, Bergholm R, Johansson LM, et al. Prediction of non-alcoholic fatty liver disease and liver fat using metabolic and genetic factors. Gastroenterology. 2009;137:865\u2013872","journal-title":"Gastroenterology"},{"key":"10661_CR8","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1097\/HEP.0000000000000419","volume":"78","author":"LA Adams","year":"2023","unstructured":"Adams LA, Schulte PJ, Allen AM. Use of noninvasive scores to predict hepatic steatosis: flaws and caveats. Hepatology. 2023;78:1029\u20131031","journal-title":"Hepatology"},{"key":"10661_CR9","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1002\/hep.24452","volume":"54","author":"R Hernaez","year":"2011","unstructured":"Hernaez R, Lazo M, Bonekamp S, Kamel I, Brancati FL, Guallar E, et al. Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: a meta-analysis. Hepatology. 2011;54:1082\u20131090","journal-title":"Hepatology"},{"key":"10661_CR10","doi-asserted-by":"publisher","first-page":"83","DOI":"10.14366\/usg.21076","volume":"41","author":"JK Jang","year":"2022","unstructured":"Jang JK, Choi SH, Lee JS, Kim SY, Lee SS, Kim KW. Accuracy of the ultrasound attenuation coefficient for the evaluation of hepatic steatosis: a systematic review and meta-analysis of prospective studies. Ultrasonography. 2022;41:83\u201392","journal-title":"Ultrasonography"},{"key":"10661_CR11","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/S2468-1253(20)30357-5","volume":"6","author":"D Petroff","year":"2021","unstructured":"Petroff D, Blank V, Newsome PN, Shalimar VCS, Thiele M, de Ledinghen V, et al. Assessment of hepatic steatosis by controlled attenuation parameter using the M and XL probes: an individual patient data meta-analysis. Lancet Gastroenterol Hepatol. 2021;6:185\u2013198","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"945\u2013953","key":"10661_CR12","volume":"18","author":"S Harry","year":"2020","unstructured":"Harry S, Lai LL, Nik Mustapha NR, Abdul Aziz YF, Vijayananthan A, Rahmat K, et al. volumetric liver fat fraction determines grade of steatosis more accurately than controlled attenuation parameter in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2020;18(945\u2013953): e942","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10661_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2021.100381","volume":"3","author":"P Garteiser","year":"2021","unstructured":"Garteiser P, Castera L, Coupaye M, Doblas S, Calabrese D, Dioguardi Burgio M, et al. Prospective comparison of transient elastography, MRI and serum scores for grading steatosis and detecting non-alcoholic steatohepatitis in bariatric surgery candidates. JHEP Rep. 2021;3: 100381","journal-title":"JHEP Rep"},{"key":"10661_CR14","doi-asserted-by":"publisher","first-page":"100928","DOI":"10.1016\/j.jhepr.2023.100928","volume":"6","author":"S Qadri","year":"2023","unstructured":"Qadri S, Vartianen E, Lahelma M, Porthan K, Tang A, Idilman I, et al. Marked difference in liver fat measured by histology vs. magnetic resonance proton density fat fraction: a meta-analysis. JHEP Rep. 2023;6:100928","journal-title":"JHEP Rep"},{"key":"10661_CR15","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1053\/j.gastro.2017.06.005","volume":"153","author":"MS Middleton","year":"2017","unstructured":"Middleton MS, Heba ER, Hooker CA, Bashir MR, Fowler KJ, Sandrasegaran K, et al. Agreement between magnetic resonance imaging proton density fat fraction measurements and pathologist-assigned steatosis grades of liver biopsies from adults with nonalcoholic steatohepatitis. Gastroenterology. 2017;153:753\u2013761","journal-title":"Gastroenterology"},{"key":"10661_CR16","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1136\/gutjnl-2021-324264","volume":"71","author":"N Tamaki","year":"2022","unstructured":"Tamaki N, Munaganuru N, Jung J, Yonan AQ, Loomba RR, Bettencourt R, et al. Clinical utility of 30% relative decline in MRI-PDFF in predicting fibrosis regression in non-alcoholic fatty liver disease. Gut. 2022;71:983\u2013990","journal-title":"Gut"},{"issue":"2274\u20132283","key":"10661_CR17","volume":"19","author":"JG Stine","year":"2021","unstructured":"Stine JG, Munaganuru N, Barnard A, Wang JL, Kaulback K, Argo CK, et al. Change in MRI-PDFF and histologic response in patients with nonalcoholic steatohepatitis: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2021;19(2274\u20132283): e2275","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10661_CR18","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1111\/liv.15626","volume":"43","author":"JH Wang","year":"2023","unstructured":"Wang JH, Ou HY, Yen YH, Hung CH, Lu SN. Usefulness of controlled attenuation parameter in monitoring clinically relevant decline of hepatic steatosis for non-alcoholic fatty liver disease. Liver Int. 2023;43:1901\u20131908","journal-title":"Liver Int"},{"issue":"1611\u20131625","key":"10661_CR19","volume":"158","author":"RS Taylor","year":"2020","unstructured":"Taylor RS, Taylor RJ, Bayliss S, Hagstrom H, Nasr P, Schattenberg JM, et al. Association between fibrosis stage and outcomes of patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis. Gastroenterology. 2020;158(1611\u20131625): e1612","journal-title":"Gastroenterology"},{"key":"10661_CR20","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1053\/j.gastro.2021.07.049","volume":"161","author":"F Kanwal","year":"2021","unstructured":"Kanwal F, Shubrook JH, Adams LA, Pfotenhauer K, Wai-Sun Wong V, Wright E, et al. Clinical care pathway for the risk stratification and management of patients with nonalcoholic fatty liver disease. Gastroenterology. 2021;161:1657\u20131669","journal-title":"Gastroenterology"},{"key":"10661_CR21","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1111\/liv.15404","volume":"42","author":"VWS Wong","year":"2022","unstructured":"Wong VWS, Zelber-Sagi S, Cusi K, Carrieri P, Wright E, Crespo J, et al. Management of NAFLD in primary care settings. Liver Int. 2022;42:2377\u20132389","journal-title":"Liver Int"},{"key":"10661_CR22","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1136\/gutjnl-2021-324243","volume":"71","author":"FE Mozes","year":"2022","unstructured":"Mozes FE, Lee JA, Selvaraj EA, Jayaswal ANA, Trauner M, Boursier J, et al. Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis. Gut. 2022;71:1006\u20131019","journal-title":"Gut"},{"issue":"90\u2013102","key":"10661_CR23","volume":"21","author":"VW Wong","year":"2023","unstructured":"Wong VW, Tak WY, Goh GBB, Cheng PN, Lawitz EJ, Younossi ZM, et al. Performance of noninvasive tests of fibrosis among asians, hispanic, and non-hispanic whites in the STELLAR trials. Clin Gastroenterol Hepatol. 2023;21(90\u2013102): e106","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10661_CR24","doi-asserted-by":"publisher","first-page":"2026","DOI":"10.1016\/j.cgh.2023.03.042","volume":"21","author":"AJ Sanyal","year":"2023","unstructured":"Sanyal AJ, Castera L, Wong VW. Noninvasive assessment of liver fibrosis in NAFLD. Clin Gastroenterol Hepatol. 2023;21:2026\u20132039","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2570\u20132580","key":"10661_CR25","volume":"17","author":"WK Chan","year":"2019","unstructured":"Chan WK, Treeprasertsuk S, Goh GB, Fan JG, Song MJ, Charatcharoenwitthaya P, et al. Optimizing Use of nonalcoholic fatty liver disease fibrosis score, fibrosis-4 score, and liver stiffness measurement to identify patients with advanced fibrosis. Clin Gastroenterol Hepatol. 2019;17(2570\u20132580): e2537","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10661_CR26","doi-asserted-by":"publisher","first-page":"2057","DOI":"10.1136\/gutjnl-2018-317334","volume":"68","author":"VW Wong","year":"2019","unstructured":"Wong VW, Irles M, Wong GL, Shili S, Chan AW, Merrouche W, et al. Unified interpretation of liver stiffness measurement by M and XL probes in non-alcoholic fatty liver disease. Gut. 2019;68:2057\u20132064","journal-title":"Gut"},{"key":"10661_CR27","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1038\/s41575-018-0014-9","volume":"15","author":"VW Wong","year":"2018","unstructured":"Wong VW, Adams LA, de Ledinghen V, Wong GL, Sookoian S. Noninvasive biomarkers in NAFLD and NASH - current progress and future promise. Nat Rev Gastroenterol Hepatol. 2018;15:461\u2013478","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10661_CR28","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1136\/gutjnl-2015-309265","volume":"65","author":"R Kwok","year":"2016","unstructured":"Kwok R, Choi KC, Wong GL, Zhang Y, Chan HL, Luk AO, et al. Screening diabetic patients for non-alcoholic fatty liver disease with controlled attenuation parameter and liver stiffness measurements: a prospective cohort study. Gut. 2016;65:1359\u20131368","journal-title":"Gut"},{"key":"10661_CR29","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1111\/jgh.14577","volume":"34","author":"LL Lai","year":"2019","unstructured":"Lai LL, Wan Yusoff WNI, Vethakkan SR, Nik Mustapha NR, Mahadeva S, Chan WK. Screening for non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus using transient elastography. J Gastroenterol Hepatol. 2019;34:1396\u20131403","journal-title":"J Gastroenterol Hepatol"},{"key":"10661_CR30","doi-asserted-by":"publisher","first-page":"2364","DOI":"10.1136\/gutjnl-2023-330269","volume":"72","author":"X Zhang","year":"2023","unstructured":"Zhang X, Yip TC, Wong GL, Leow WX, Liang LY, Lim LL, et al. Clinical care pathway to detect advanced liver disease in patients with type 2 diabetes through automated fibrosis score calculation and electronic reminder messages: a randomised controlled trial. Gut. 2023;72:2364\u20132371","journal-title":"Gut"},{"key":"10661_CR31","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1111\/apt.17722","volume":"58","author":"JTK Cheung","year":"2023","unstructured":"Cheung JTK, Zhang X, Wong GL, Yip TC, Lin H, Li G, et al. MAFLD fibrosis score: Using routine measures to identify advanced fibrosis in metabolic-associated fatty liver disease. Aliment Pharmacol Ther. 2023;58:1194\u20131204","journal-title":"Aliment Pharmacol Ther"},{"key":"10661_CR32","doi-asserted-by":"publisher","first-page":"2656","DOI":"10.1038\/s41591-023-02539-6","volume":"29","author":"AJ Sanyal","year":"2023","unstructured":"Sanyal AJ, Shankar SS, Yates KP, Bolognese J, Daly E, Dehn CA, et al. Diagnostic performance of circulating biomarkers for non-alcoholic steatohepatitis. Nat Med. 2023;29:2656\u20132664","journal-title":"Nat Med"},{"key":"10661_CR33","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1016\/j.jhep.2023.04.031","volume":"79","author":"SA Harrison","year":"2023","unstructured":"Harrison SA, Ratziu V, Magnanensi J, Hajji Y, Deledicque S, Majd Z, et al. NIS2+, an optimisation of the blood-based biomarker NIS4(R) technology for the detection of at-risk NASH: A prospective derivation and validation study. J Hepatol. 2023;79:758\u2013767","journal-title":"J Hepatol"},{"key":"10661_CR34","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1111\/apt.14621","volume":"47","author":"J Boursier","year":"2018","unstructured":"Boursier J, Anty R, Vonghia L, Moal V, Vanwolleghem T, Canivet CM, et al. Screening for therapeutic trials and treatment indication in clinical practice: MACK-3, a new blood test for the diagnosis of fibrotic NASH. Aliment Pharmacol Ther. 2018;47:1387\u20131396","journal-title":"Aliment Pharmacol Ther"},{"key":"10661_CR35","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/j.jhep.2022.11.029","volume":"78","author":"AJ Sanyal","year":"2023","unstructured":"Sanyal AJ, Williams SA, Lavine JE, Neuschwander-Tetri BA, Alexander L, Ostroff R, et al. Defining the serum proteomic signature of hepatic steatosis, inflammation, ballooning and fibrosis in non-alcoholic fatty liver disease. J Hepatol. 2023;78:693\u2013703","journal-title":"J Hepatol"},{"key":"10661_CR36","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1016\/S2468-1253(23)00017-1","volume":"8","author":"Y Vali","year":"2023","unstructured":"Vali Y, Lee J, Boursier J, Petta S, Wonders K, Tiniakos D, et al. Biomarkers for staging fibrosis and non-alcoholic steatohepatitis in non-alcoholic fatty liver disease (the LITMUS project): a comparative diagnostic accuracy study. Lancet Gastroenterol Hepatol. 2023;8:714\u2013725","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10661_CR37","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1016\/j.jhep.2022.07.020","volume":"77","author":"BK Kim","year":"2022","unstructured":"Kim BK, Tamaki N, Imajo K, Yoneda M, Sutter N, Jung J, et al. Head-to-head comparison between MEFIB, MAST, and FAST for detecting stage 2 fibrosis or higher among patients with NAFLD. J Hepatol. 2022;77:1482\u20131490","journal-title":"J Hepatol"},{"key":"10661_CR38","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/S2468-1253(19)30383-8","volume":"5","author":"PN Newsome","year":"2020","unstructured":"Newsome PN, Sasso M, Deeks JJ, Paredes A, Boursier J, Chan WK, et al. FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study. Lancet Gastroenterol Hepatol. 2020;5:362\u2013373","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"2451\u20132461","key":"10661_CR39","volume":"20","author":"A Andersson","year":"2022","unstructured":"Andersson A, Kelly M, Imajo K, Nakajima A, Fallowfield JA, Hirschfield G, et al. Clinical utility of magnetic resonance imaging biomarkers for identifying nonalcoholic steatohepatitis patients at high risk of progression: a multicenter pooled data and meta-analysis. Clin Gastroenterol Hepatol. 2022;20(2451\u20132461): e2453","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10661_CR40","doi-asserted-by":"publisher","first-page":"2757","DOI":"10.1007\/s10620-023-07896-3","volume":"68","author":"LC Bertot","year":"2023","unstructured":"Bertot LC, Jeffrey GP, de Boer B, Wang Z, Huang Y, Garas G, et al. Comparative accuracy of clinical fibrosis markers, hepascore and fibroscan(R) to detect advanced fibrosis in patients with nonalcoholic fatty liver disease. Dig Dis Sci. 2023;68:2757\u20132767","journal-title":"Dig Dis Sci"},{"key":"10661_CR41","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1177\/2050640619865133","volume":"7","author":"K Staufer","year":"2019","unstructured":"Staufer K, Halilbasic E, Spindelboeck W, Eilenberg M, Prager G, Stadlbauer V, et al. Evaluation and comparison of six noninvasive tests for prediction of significant or advanced fibrosis in nonalcoholic fatty liver disease. United Eur Gastroenterol J. 2019;7:1113\u20131123","journal-title":"United Eur Gastroenterol J"},{"key":"10661_CR42","doi-asserted-by":"publisher","first-page":"5219","DOI":"10.1038\/s41467-023-40328-4","volume":"14","author":"J Boursier","year":"2023","unstructured":"Boursier J, Roux M, Costentin C, Chaigneau J, Fournier-Poizat C, Trylesinski A, et al. Practical diagnosis of cirrhosis in non-alcoholic fatty liver disease using currently available non-invasive fibrosis tests. Nat Commun. 2023;14:5219","journal-title":"Nat Commun"},{"key":"10661_CR43","doi-asserted-by":"publisher","DOI":"10.1097\/HC9.0000000000000055","volume":"7","author":"M Noureddin","year":"2023","unstructured":"Noureddin M, Mena E, Vuppalanchi R, Samala N, Wong M, Pacheco F, et al. Increased accuracy in identifying NAFLD with advanced fibrosis and cirrhosis: independent validation of the Agile 3+ and 4 scores. Hepatol Commun. 2023;7: e0055","journal-title":"Hepatol Commun"},{"key":"10661_CR44","doi-asserted-by":"publisher","first-page":"984","DOI":"10.14309\/ajg.0000000000001059","volume":"116","author":"M Eslam","year":"2021","unstructured":"Eslam M, Wong GL, Hashem AM, Chan HL, Nielsen MJ, Leeming DJ, et al. A sequential algorithm combining ADAPT and liver stiffness can stage metabolic-associated fatty liver disease in hospital-based and primary care patients. Am J Gastroenterol. 2021;116:984\u2013993","journal-title":"Am J Gastroenterol"},{"key":"10661_CR45","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.jhep.2023.04.002","volume":"79","author":"M Kjaergaard","year":"2023","unstructured":"Kjaergaard M, Lindvig KP, Thorhauge KH, Andersen P, Hansen JK, Kastrup N, et al. Using the ELF test, FIB-4 and NAFLD fibrosis score to screen the population for liver disease. J Hepatol. 2023;79:277\u2013286","journal-title":"J Hepatol"},{"issue":"1013\u20131022","key":"10661_CR46","volume":"21","author":"T Ito","year":"2023","unstructured":"Ito T, Nguyen VH, Tanaka T, Park H, Yeh ML, Kawanaka M, et al. Poor diagnostic efficacy of noninvasive tests for advanced fibrosis in obese or younger than 60 diabetic NAFLD patients. Clin Gastroenterol Hepatol. 2023;21(1013\u20131022): e1016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10661_CR47","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.29568","volume":"6","author":"H Park","year":"2023","unstructured":"Park H, Yoon EL, Ito T, Jo AJ, Kim M, Lee J, et al. Diagnostic performance of the fibrosis-4 index and nonalcoholic fatty liver disease fibrosis score in lean adults with nonalcoholic fatty liver disease. JAMA Netw Open. 2023;6: e2329568","journal-title":"JAMA Netw Open"},{"key":"10661_CR48","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1016\/j.jhep.2021.04.044","volume":"75","author":"EA Selvaraj","year":"2021","unstructured":"Selvaraj EA, Mozes FE, Jayaswal ANA, Zafarmand MH, Vali Y, Lee JA, et al. Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: a systematic review and meta-analysis. J Hepatol. 2021;75:770\u2013785","journal-title":"J Hepatol"},{"key":"10661_CR49","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.jhep.2018.09.024","volume":"70","author":"S Jayakumar","year":"2019","unstructured":"Jayakumar S, Middleton MS, Lawitz EJ, Mantry PS, Caldwell SH, Arnold H, et al. Longitudinal correlations between MRE, MRI-PDFF, and liver histology in patients with non-alcoholic steatohepatitis: analysis of data from a phase II trial of selonsertib. J Hepatol. 2019;70:133\u2013141","journal-title":"J Hepatol"},{"key":"10661_CR50","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1002\/hep.30974","volume":"71","author":"VH Ajmera","year":"2020","unstructured":"Ajmera VH, Liu A, Singh S, Yachoa G, Ramey M, Bhargava M, et al. Clinical utility of an increase in magnetic resonance elastography in predicting fibrosis progression in nonalcoholic fatty liver disease. Hepatology. 2020;71:849\u2013860","journal-title":"Hepatology"},{"key":"10661_CR51","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1016\/j.jhep.2021.10.029","volume":"76","author":"ME Rinella","year":"2022","unstructured":"Rinella ME, Dufour JF, Anstee QM, Goodman Z, Younossi Z, Harrison SA, et al. Non-invasive evaluation of response to obeticholic acid in patients with NASH: Results from the REGENERATE study. J Hepatol. 2022;76:536\u2013548","journal-title":"J Hepatol"},{"key":"10661_CR52","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1111\/liv.15255","volume":"42","author":"W Balkhed","year":"2022","unstructured":"Balkhed W, Aberg FO, Nasr P, Ekstedt M, Kechagias S. Repeated measurements of non-invasive fibrosis tests to monitor the progression of non-alcoholic fatty liver disease: a long-term follow-up study. Liver Int. 2022;42:1545\u20131556","journal-title":"Liver Int"},{"key":"10661_CR53","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1016\/j.jhep.2021.09.024","volume":"76","author":"TC Yip","year":"2022","unstructured":"Yip TC, Lee HW, Chan WK, Wong GL, Wong VW. Asian perspective on NAFLD-associated HCC. J Hepatol. 2022;76:726\u2013734","journal-title":"J Hepatol"},{"key":"10661_CR54","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1016\/S2468-1253(23)00141-3","volume":"8","author":"FE Mozes","year":"2023","unstructured":"Mozes FE, Lee JA, Vali Y, Alzoubi O, Staufer K, Trauner M, et al. Performance of non-invasive tests and histology for the prediction of clinical outcomes in patients with non-alcoholic fatty liver disease: an individual participant data meta-analysis. Lancet Gastroenterol Hepatol. 2023;8:704\u2013713","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"1293\u20131302","key":"10661_CR55","volume":"21","author":"G Pennisi","year":"2023","unstructured":"Pennisi G, Enea M, Pandolfo A, Celsa C, Antonucci M, Ciccioli C, et al. AGILE 3+ score for the diagnosis of advanced fibrosis and for predicting liver-related events in NAFLD. Clin Gastroenterol Hepatol. 2023;21(1293\u20131302): e1295","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1079\u20131089","key":"10661_CR56","volume":"163","author":"V Ajmera","year":"2022","unstructured":"Ajmera V, Kim BK, Yang K, Majzoub AM, Nayfeh T, Tamaki N, et al. Liver stiffness on magnetic resonance elastography and the MEFIB index and liver-related outcomes in nonalcoholic fatty liver disease: a systematic review and meta-analysis of individual participants. Gastroenterology. 2022;163(1079\u20131089): e1075","journal-title":"Gastroenterology"},{"key":"10661_CR57","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/j.jhep.2020.06.007","volume":"73","author":"H Hagstrom","year":"2020","unstructured":"Hagstrom H, Talback M, Andreasson A, Walldius G, Hammar N. Repeated FIB-4 measurements can help identify individuals at risk of severe liver disease. J Hepatol. 2020;73:1023\u20131029","journal-title":"J Hepatol"},{"key":"10661_CR58","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.jhep.2022.10.035","volume":"78","author":"G Cholankeril","year":"2023","unstructured":"Cholankeril G, Kramer JR, Chu J, Yu X, Balakrishnan M, Li L, et al. Longitudinal changes in fibrosis markers are associated with risk of cirrhosis and hepatocellular carcinoma in non-alcoholic fatty liver disease. J Hepatol. 2023;78:493\u2013500","journal-title":"J Hepatol"},{"key":"10661_CR59","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1136\/gutjnl-2022-327777","volume":"72","author":"R Loomba","year":"2023","unstructured":"Loomba R, Huang DQ, Sanyal AJ, Anstee QM, Trauner M, Lawitz EJ, et al. Liver stiffness thresholds to predict disease progression and clinical outcomes in bridging fibrosis and cirrhosis. Gut. 2023;72:581\u2013589","journal-title":"Gut"},{"issue":"1915\u20131924","key":"10661_CR60","volume":"19","author":"T Gidener","year":"2021","unstructured":"Gidener T, Ahmed OT, Larson JJ, Mara KC, Therneau TM, Venkatesh SK, et al. Liver stiffness by magnetic resonance elastography predicts future cirrhosis, decompensation, and death in NAFLD. Clin Gastroenterol Hepatol. 2021;19(1915\u20131924): e1916","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10661_CR61","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1007\/s00535-023-02049-9","volume":"59","author":"T Kobayashi","year":"2024","unstructured":"Kobayashi T, Iwaki M, Nogami A, Kawamura N, Honda Y, Ogawa Y, et al. Prediction of outcomes in patients with metabolic dysfunction-associated steatotic liver disease based on initial measurements and subsequent changes in magnetic resonance elastography. J Gastroenterol. 2024;59:56\u201365","journal-title":"J Gastroenterol"},{"key":"10661_CR62","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/j.jhep.2021.12.022","volume":"76","author":"R de Franchis","year":"2022","unstructured":"de Franchis R, Bosch J, Garcia-Tsao G, Reiberger T, Ripoll C, Baveno VII Faculty. Baveno VII\u2014Renewing consensus in portal hypertension. J Hepatol. 2022;76:959\u2013974","journal-title":"J Hepatol"},{"key":"10661_CR63","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1111\/apt.17699","volume":"58","author":"H Lin","year":"2023","unstructured":"Lin H, Lai JC, Wong GL, Delamarre A, Ahn SH, Li G, et al. Risk and predictors of hepatic decompensation in grey zone patients by the Baveno VII criteria: A competing risk analysis. Aliment Pharmacol Ther. 2023;58:920\u2013928","journal-title":"Aliment Pharmacol Ther"},{"key":"10661_CR64","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1016\/S2468-1253(23)00150-4","volume":"8","author":"E Dajti","year":"2023","unstructured":"Dajti E, Ravaioli F, Zykus R, Rautou PE, Elkrief L, Grgurevic I, et al. Accuracy of spleen stiffness measurement for the diagnosis of clinically significant portal hypertension in patients with compensated advanced chronic liver disease: a systematic review and individual patient data meta-analysis. Lancet Gastroenterol Hepatol. 2023;8:816\u2013828","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10661_CR65","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1007\/s00535-020-01686-8","volume":"55","author":"JW Wai","year":"2020","unstructured":"Wai JW, Fu C, Wong VW. Confounding factors of non-invasive tests for nonalcoholic fatty liver disease. J Gastroenterol. 2020;55:731\u2013741","journal-title":"J Gastroenterol"},{"key":"10661_CR66","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71:209\u2013249","journal-title":"CA Cancer J Clin"},{"key":"10661_CR67","doi-asserted-by":"publisher","DOI":"10.1097\/HC9.0000000000000251","volume":"7","author":"JM Paik","year":"2023","unstructured":"Paik JM, Henry L, Younossi Y, Ong J, Alqahtani S, Younossi ZM. The burden of nonalcoholic fatty liver disease (NAFLD) is rapidly growing in every region of the world from 1990 to 2019. Hepatol Commun. 2023;7: e0251","journal-title":"Hepatol Commun"},{"key":"10661_CR68","first-page":"S239","volume":"78","author":"ZM Younossi","year":"2023","unstructured":"Younossi ZM, Al Shabeeb R, Eberly KE, Shah D, Nguyen V, Ong J, et al. Non-alcoholic steatohepatitis (NASH) has become the most common indication for liver transplantation among candidates with hepatocellular carcinoma in the United States. Hepatology. 2023;78:S239","journal-title":"Hepatology"},{"issue":"124\u2013131","key":"10661_CR69","volume":"14","author":"S Mittal","year":"2016","unstructured":"Mittal S, El-Serag HB, Sada YH, Kanwal F, Duan Z, Temple S, et al. Hepatocellular carcinoma in the absence of cirrhosis in United States Veterans is associated with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2016;14(124\u2013131): e121","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10661_CR70","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1007\/s10620-022-07565-x","volume":"68","author":"J Chu","year":"2023","unstructured":"Chu J, Cholankeril G, Yu X, Rana A, Natarajan Y, El-Serag HB, et al. Clinical course and outcomes of patients with nonalcoholic fatty liver disease-related hepatocellular cancer (NAFLD-HCC). Dig Dis Sci. 2023;68:1060\u20131070","journal-title":"Dig Dis Sci"},{"key":"10661_CR71","first-page":"S945","volume":"78","author":"R Manikat","year":"2023","unstructured":"Manikat R, Tran S, Kam LY, Dronamraju D, Cheung RC, Nguyen MH. Diagnosis is delayed: pericomplication diagnosis of nonalcoholic fatty liver disease. Hepatology. 2023;78:S945","journal-title":"Hepatology"},{"key":"10661_CR72","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1111\/joim.13035","volume":"287","author":"MH Le","year":"2020","unstructured":"Le MH, Yeo YH, Cheung R, Wong VW, Nguyen MH. Ethnic influence on nonalcoholic fatty liver disease prevalence and lack of disease awareness in the United States, 2011\u20132016. J Intern Med. 2020;287:711\u2013722","journal-title":"J Intern Med"},{"key":"10661_CR73","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1002\/ijc.26165","volume":"130","author":"C Wang","year":"2012","unstructured":"Wang C, Wang X, Gong G, Ben Q, Qiu W, Chen Y, et al. Increased risk of hepatocellular carcinoma in patients with diabetes mellitus: a systematic review and meta-analysis of cohort studies. Int J Cancer. 2012;130:1639\u20131648","journal-title":"Int J Cancer"},{"key":"10661_CR74","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1038\/sj.bjc.6603932","volume":"97","author":"SC Larsson","year":"2007","unstructured":"Larsson SC, Wolk A. Overweight, obesity and risk of liver cancer: a meta-analysis of cohort studies. Br J Cancer. 2007;97:1005\u20131008","journal-title":"Br J Cancer"},{"key":"10661_CR75","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/j.jhep.2019.06.021","volume":"71","author":"ZM Younossi","year":"2019","unstructured":"Younossi ZM, Golabi P, de Avila L, Paik JM, Srishord M, Fukui N, et al. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis. J Hepatol. 2019;71:793\u2013801","journal-title":"J Hepatol"},{"key":"10661_CR76","doi-asserted-by":"publisher","first-page":"1950","DOI":"10.1002\/oby.23263","volume":"29","author":"D Barb","year":"2021","unstructured":"Barb D, Repetto EM, Stokes ME, Shankar SS, Cusi K. Type 2 diabetes mellitus increases the risk of hepatic fibrosis in individuals with obesity and nonalcoholic fatty liver disease. Obesity (Silver Spring). 2021;29:1950\u20131960","journal-title":"Obesity (Silver Spring)"},{"key":"10661_CR77","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1111\/apt.15830","volume":"52","author":"ZM Younossi","year":"2020","unstructured":"Younossi ZM, Corey KE, Alkhouri N, Noureddin M, Jacobson I, Lam B, et al. Clinical assessment for high-risk patients with non-alcoholic fatty liver disease in primary care and diabetology practices. Aliment Pharmacol Ther. 2020;52:513\u2013526","journal-title":"Aliment Pharmacol Ther"},{"key":"10661_CR78","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1016\/j.eprac.2022.03.010","volume":"28","author":"K Cusi","year":"2022","unstructured":"Cusi K, Isaacs S, Barb D, Basu R, Caprio S, Garvey WT, et al. American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings: Co-Sponsored by the American Association for the Study of Liver Diseases (AASLD). Endocr Pract. 2022;28:528\u2013562","journal-title":"Endocr Pract"},{"key":"10661_CR79","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","volume":"77","author":"ME Rinella","year":"2023","unstructured":"Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, Abdelmalek MF, Caldwell S, Barb D, et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023;77:1797\u20131835","journal-title":"Hepatology"},{"key":"10661_CR80","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1038\/s41575-023-00818-8","volume":"20","author":"DQ Huang","year":"2023","unstructured":"Huang DQ, Singal AG, Kanwal F, Lampertico P, Buti M, Sirlin CB, et al. Hepatocellular carcinoma surveillance - utilization, barriers and the impact of changing aetiology. Nat Rev Gastroenterol Hepatol. 2023;20:797\u2013809","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10661_CR81","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-023-10616-8","author":"DQ Huang","year":"2023","unstructured":"Huang DQ, Tran S, Barnett S, Zou B, Yeo YH, Cheung R, et al. Incidence and predictors of hepatocellular carcinoma in NAFLD without diagnosed cirrhosis: a nationwide real-world U.S. study. Hepatol Int. 2023. https:\/\/doi.org\/10.1007\/s12072-023-10616-8. (Epub ahead of print)","journal-title":"Hepatol Int"},{"key":"10661_CR82","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1007\/s00535-021-01828-6","volume":"56","author":"M Yoneda","year":"2021","unstructured":"Yoneda M, Yamamoto T, Honda Y, Imajo K, Ogawa Y, Kessoku T, et al. Risk of cardiovascular disease in patients with fatty liver disease as defined from the metabolic dysfunction associated fatty liver disease or nonalcoholic fatty liver disease point of view: a retrospective nationwide claims database study in Japan. J Gastroenterol. 2021;56:1022\u20131032","journal-title":"J Gastroenterol"},{"key":"10661_CR83","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1002\/hep.32499","volume":"76","author":"ZM Younossi","year":"2022","unstructured":"Younossi ZM, Paik JM, Al Shabeeb R, Golabi P, Younossi I, Henry L. Are there outcome differences between NAFLD and metabolic-associated fatty liver disease? Hepatology. 2022;76:1423\u20131437","journal-title":"Hepatology"},{"issue":"2588\u20132596","key":"10661_CR84","volume":"21","author":"L de Avila","year":"2023","unstructured":"de Avila L, Henry L, Paik JM, Ijaz N, Weinstein AA, Younossi ZM. Nonalcoholic fatty liver disease is independently associated with higher all-cause and cause-specific mortality. Clin Gastroenterol Hepatol. 2023;21(2588\u20132596): e2583","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10661_CR85","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1002\/hep.31040","volume":"72","author":"CS Alvarez","year":"2020","unstructured":"Alvarez CS, Graubard BI, Thistle JE, Petrick JL, McGlynn KA. Attributable fractions of nonalcoholic fatty liver disease for mortality in the United States: results from the third national health and nutrition examination survey with 27 years of follow-up. Hepatology. 2020;72:430\u2013440","journal-title":"Hepatology"},{"key":"10661_CR86","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1161\/CIRCULATIONAHA.121.053730","volume":"145","author":"NR Hasbani","year":"2022","unstructured":"Hasbani NR, Ligthart S, Brown MR, Heath AS, Bebo A, Ashley KE, et al. American Heart Association\u2019s life\u2019s simple 7: lifestyle recommendations, polygenic risk, and lifetime risk of coronary heart disease. Circulation. 2022;145:808\u2013818","journal-title":"Circulation"},{"key":"10661_CR87","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1111\/apt.15580","volume":"51","author":"JM Paik","year":"2020","unstructured":"Paik JM, Deshpande R, Golabi P, Younossi I, Henry L, Younossi ZM. The impact of modifiable risk factors on the long-term outcomes of non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2020;51:291\u2013304","journal-title":"Aliment Pharmacol Ther"},{"key":"10661_CR88","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.1161\/CIR.0000000000001078","volume":"146","author":"DM Lloyd-Jones","year":"2022","unstructured":"Lloyd-Jones DM, Allen NB, Anderson CAM, Black T, Brewer LC, Foraker RE, et al. Life\u2019s essential 8: updating and enhancing the American Heart Association\u2019s construct of cardiovascular health: a Presidential Advisory From the American Heart Association. Circulation. 2022;146:e18\u2013e43","journal-title":"Circulation"},{"key":"10661_CR89","doi-asserted-by":"publisher","first-page":"2646","DOI":"10.1111\/liv.15437","volume":"42","author":"ZM Younossi","year":"2022","unstructured":"Younossi ZM, Paik JM, Golabi P, Younossi Y, Henry L, Nader F. The impact of fatigue on mortality of patients with non-alcoholic fatty liver disease: data from National Health and nutrition examination survey 2005\u20132010 and 2017\u20132018. Liver Int. 2022;42:2646\u20132661","journal-title":"Liver Int"},{"key":"10661_CR90","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1038\/s41575-023-00800-4","volume":"20","author":"ZM Younossi","year":"2023","unstructured":"Younossi ZM, Zelber-Sagi S, Henry L, Gerber LH. Lifestyle interventions in nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol. 2023;20:708\u2013722","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10661_CR91","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1111\/apt.17308","volume":"57","author":"A Henry","year":"2023","unstructured":"Henry A, Paik JM, Austin P, Eberly KE, Golabi P, Younossi I, et al. Vigorous physical activity provides protection against all-cause deaths among adults patients with nonalcoholic fatty liver disease (NAFLD). Aliment Pharmacol Ther. 2023;57:709\u2013722","journal-title":"Aliment Pharmacol Ther"},{"key":"10661_CR92","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.ejca.2022.06.051","volume":"173","author":"JA Thomas","year":"2022","unstructured":"Thomas JA, Kendall BJ, Dalais C, Macdonald GA, Thrift AP. Hepatocellular and extrahepatic cancers in non-alcoholic fatty liver disease: a systematic review and meta-analysis. Eur J Cancer. 2022;173:250\u2013262","journal-title":"Eur J Cancer"},{"key":"10661_CR93","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1002\/hep4.1408","volume":"3","author":"MH Le","year":"2019","unstructured":"Le MH, Yeo YH, Henry L, Nguyen MH. Nonalcoholic fatty liver disease and renal function impairment: a cross-sectional population-based study on its relationship from 1999 to 2016. Hepatol Commun. 2019;3:1334\u20131346","journal-title":"Hepatol Commun"},{"key":"10661_CR94","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2020.154433","volume":"115","author":"DQ Sun","year":"2021","unstructured":"Sun DQ, Jin Y, Wang TY, Zheng KI, Rios RS, Zhang HY, et al. MAFLD and risk of CKD. Metabolism. 2021;115: 154433","journal-title":"Metabolism"},{"key":"10661_CR95","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1056\/NEJMoa2029349","volume":"385","author":"AJ Sanyal","year":"2021","unstructured":"Sanyal AJ, Van Natta ML, Clark J, Neuschwander-Tetri BA, Diehl A, Dasarathy S, et al. Prospective study of outcomes in adults with nonalcoholic fatty liver disease. N Engl J Med. 2021;385:1559\u20131569","journal-title":"N Engl J Med"},{"key":"10661_CR96","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1007\/s00592-023-02058-3","volume":"60","author":"MC Moh","year":"2023","unstructured":"Moh MC, Pek SLT, Sze KCP, Low S, Subramaniam T, Ang K, et al. Associations of non-invasive indices of liver steatosis and fibrosis with progressive kidney impairment in adults with type 2 diabetes. Acta Diabetol. 2023;60:827\u2013835","journal-title":"Acta Diabetol"},{"key":"10661_CR97","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.3390\/biomedicines11071928","volume":"11","author":"J Bae","year":"2023","unstructured":"Bae J, Lee BW. Significance of diabetic kidney disease biomarkers in predicting metabolic-associated fatty liver disease. Biomedicines. 2023;11:1928","journal-title":"Biomedicines"},{"key":"10661_CR98","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2022.100525","volume":"4","author":"Z Younossi","year":"2022","unstructured":"Younossi Z, Aggarwal P, Shrestha I, Fernandes J, Johansen P, Augusto M, et al. The burden of non-alcoholic steatohepatitis: a systematic review of health-related quality of life and patient-reported outcomes. JHEP Rep. 2022;4: 100525","journal-title":"JHEP Rep"},{"key":"10661_CR99","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/j.jceh.2022.12.005","volume":"13","author":"ZM Younossi","year":"2023","unstructured":"Younossi ZM, Paik JM, Henry L, Yang J, Fernandes G, Stepanova M, et al. The Growing Economic and Clinical Burden of Nonalcoholic Steatohepatitis (NASH) in the United States. J Clin Exp Hepatol. 2023;13:454\u2013467","journal-title":"J Clin Exp Hepatol"},{"key":"10661_CR100","doi-asserted-by":"publisher","first-page":"101108","DOI":"10.1016\/j.aohep.2023.101108","volume":"28","author":"JM Paik","year":"2023","unstructured":"Paik JM, Eberly KE, Kabbara K, Harring M, Younossi Y, Henry L, et al. Non-alcoholic fatty liver disease is associated with greater risk of 30-day hospital readmission in the United States (U.S.). Ann Hepatol. 2023;28:101108","journal-title":"Ann Hepatol"},{"key":"10661_CR101","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1002\/hep.30254","volume":"69","author":"ZM Younossi","year":"2019","unstructured":"Younossi ZM, Tampi R, Priyadarshini M, Nader F, Younossi IM, Racila A. Burden of illness and economic model for patients with nonalcoholic steatohepatitis in the united states. Hepatology. 2019;69:564\u2013572","journal-title":"Hepatology"},{"issue":"198\u2013210","key":"10661_CR102","volume":"16","author":"NE Rich","year":"2018","unstructured":"Rich NE, Oji S, Mufti AR, Browning JD, Parikh ND, Odewole M, et al. Racial and ethnic disparities in nonalcoholic fatty liver disease prevalence, severity, and outcomes in the united states: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2018;16(198\u2013210): e192","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10661_CR103","doi-asserted-by":"publisher","DOI":"10.2196\/34809","volume":"8","author":"H Chen","year":"2022","unstructured":"Chen H, Zhan Y, Zhang J, Cheng S, Zhou Y, Chen L, et al. The global, regional, and national burden and trends of NAFLD in 204 countries and territories: an analysis from global burden of disease 2019. JMIR Public Health Surveill. 2022;8: e34809","journal-title":"JMIR Public Health Surveill"},{"issue":"2876\u20132888","key":"10661_CR104","volume":"21","author":"M Harring","year":"2023","unstructured":"Harring M, Golabi P, Paik JM, Shah D, Racila A, Cable R, et al. Sarcopenia among patients with nonalcoholic fatty liver disease (NAFLD) is associated with advanced fibrosis. Clin Gastroenterol Hepatol. 2023;21(2876\u20132888): e2875","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10661_CR105","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1111\/liv.14719","volume":"41","author":"YC Hsieh","year":"2021","unstructured":"Hsieh YC, Joo SK, Koo BK, Lin HC, Kim W. Muscle alterations are independently associated with significant fibrosis in patients with nonalcoholic fatty liver disease. Liver Int. 2021;41:494\u2013504","journal-title":"Liver Int"},{"issue":"388\u2013397","key":"10661_CR106","volume":"21","author":"YC Hsieh","year":"2023","unstructured":"Hsieh YC, Joo SK, Koo BK, Lin HC, Lee DH, Chang MS, et al. Myosteatosis, but not sarcopenia, predisposes NAFLD subjects to early steatohepatitis and fibrosis progression. Clin Gastroenterol Hepatol. 2023;21(388\u2013397): e310","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10661_CR107","doi-asserted-by":"publisher","first-page":"1832","DOI":"10.1111\/liv.14852","volume":"41","author":"D Kim","year":"2021","unstructured":"Kim D, Wijarnpreecha K, Sandhu KK, Cholankeril G, Ahmed A. Sarcopenia in nonalcoholic fatty liver disease and all-cause and cause-specific mortality in the United States. Liver Int. 2021;41:1832\u20131840","journal-title":"Liver Int"},{"issue":"2298\u20132307","key":"10661_CR108","volume":"21","author":"HS Chun","year":"2023","unstructured":"Chun HS, Lee M, Lee HA, Lee S, Kim S, Jung YJ, et al. Risk stratification for sarcopenic obesity in subjects with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2023;21(2298\u20132307): e2218","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10661_CR109","doi-asserted-by":"publisher","first-page":"584","DOI":"10.14309\/ajg.0000000000000572","volume":"115","author":"E Han","year":"2020","unstructured":"Han E, Lee YH, Kim YD, Kim BK, Park JY, Kim DY, et al. Nonalcoholic fatty liver disease and sarcopenia are independently associated with cardiovascular risk. Am J Gastroenterol. 2020;115:584\u2013595","journal-title":"Am J Gastroenterol"},{"key":"10661_CR110","doi-asserted-by":"publisher","first-page":"1898","DOI":"10.1053\/j.gastro.2005.03.084","volume":"128","author":"V Ratziu","year":"2005","unstructured":"Ratziu V, Charlotte F, Heurtier A, Gombert S, Giral P, Bruckert E, et al. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology. 2005;128:1898\u20131906","journal-title":"Gastroenterology"},{"key":"10661_CR111","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1016\/j.jhep.2020.06.025","volume":"73","author":"BA Davison","year":"2020","unstructured":"Davison BA, Harrison SA, Cotter G, Alkhouri N, Sanyal A, Edwards C, et al. Suboptimal reliability of liver biopsy evaluation has implications for randomized clinical trials. J Hepatol. 2020;73:1322\u20131332","journal-title":"J Hepatol"},{"key":"10661_CR112","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1111\/jgh.15843","volume":"37","author":"HH Leung","year":"2022","unstructured":"Leung HH, Puspanathan P, Chan AW, Nik Mustapha NR, Wong VW, Chan WK. Reliability of the nonalcoholic steatohepatitis clinical research network and steatosis activity fibrosis histological scoring systems. J Gastroenterol Hepatol. 2022;37:1131\u20131138","journal-title":"J Gastroenterol Hepatol"},{"key":"10661_CR113","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1002\/hep.20701","volume":"41","author":"DE Kleiner","year":"2005","unstructured":"Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41:1313\u20131321","journal-title":"Hepatology"},{"key":"10661_CR114","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.12565","volume":"2","author":"DE Kleiner","year":"2019","unstructured":"Kleiner DE, Brunt EM, Wilson LA, Behling C, Guy C, Contos M, et al. Association of histologic disease activity with progression of nonalcoholic fatty liver disease. JAMA Netw Open. 2019;2: e1912565","journal-title":"JAMA Netw Open"},{"key":"10661_CR115","doi-asserted-by":"publisher","first-page":"367\u2013378e365","DOI":"10.1053\/j.gastro.2015.04.005","volume":"149","author":"E Vilar-Gomez","year":"2015","unstructured":"Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, Torres-Gonzalez A, Gra-Oramas B, Gonzalez-Fabian L, et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology. 2015;149:367-378e365 (quiz e314-365)","journal-title":"Gastroenterology"},{"key":"10661_CR116","doi-asserted-by":"publisher","first-page":"763","DOI":"10.21037\/hbsn-23-346","volume":"12","author":"WL Chan","year":"2023","unstructured":"Chan WL, Kumar CV, Chan WK. Fibroscan-AST (FAST) score and other non-invasive tests for the diagnosis of fibrotic non-alcoholic steatohepatitis. Hepatobil Surg Nutr. 2023;12:763\u2013767","journal-title":"Hepatobil Surg Nutr"},{"issue":"88\u201395","key":"10661_CR117","volume":"156","author":"R Loomba","year":"2019","unstructured":"Loomba R, Sanyal AJ, Kowdley KV, Terrault N, Chalasani NP, Abdelmalek MF, et al. Factors associated with histologic response in adult patients with nonalcoholic steatohepatitis. Gastroenterology. 2019;156(88\u201395): e85","journal-title":"Gastroenterology"}],"container-title":["Hepatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-024-10661-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12072-024-10661-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-024-10661-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,3]],"date-time":"2024-10-03T14:06:36Z","timestamp":1727964396000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12072-024-10661-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,24]]},"references-count":117,"journal-issue":{"issue":"S2","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["10661"],"URL":"https:\/\/doi.org\/10.1007\/s12072-024-10661-x","relation":{},"ISSN":["1936-0533","1936-0541"],"issn-type":[{"value":"1936-0533","type":"print"},{"value":"1936-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,24]]},"assertion":[{"value":"16 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Wah-Kheong Chan served as a consultant or advisory board member for Roche, AbbVie, Boehringer Ingelheim, Novo Nordisk and a speaker for Echosens, Viatris, and Hisky Medical. Leon Adams has served as an advisory board member or speaker for Gilead Sciences, Novo Nordisk, Pfizer, Novartis, and Roche Diagnostics. Vincent Wong served as a consultant or advisory board member for AbbVie, Boehringer Ingelheim, Echosens, Gilead Sciences, Intercept, Inventiva, Novo Nordisk, Pfizer, Sagimet Biosciences, TARGET PharmaSolutions, and Visirna and a speaker for Abbott, AbbVie, Gilead Sciences, Novo Nordisk, and Unilab. He has received a research grant from Gilead Sciences and is a co-founder of Illuminatio Medical Technology Limited. Mindie Nguyen has received research grants to institution from Pfizer, Enanta, Astra Zeneca, GSK, Delfi, Innogen, Exact Science, CurveBio, Gilead, Vir Biotech, Helio Health, National Institute of Health, Glycotest, and B.K. Kee Foundation and personal payment via advisory board or consulting from Intercept, Exact Science, Gilead, GSK, and Exelixis.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}